New drug slashes bad cholesterol in chinese adults
NCT ID NCT05888103
First seen Jan 19, 2026 · Last updated May 24, 2026 · Updated 20 times
Summary
This study tested a drug called inclisiran in 207 Chinese adults with high LDL (bad) cholesterol who were not on other cholesterol medicines. Participants received either inclisiran or a placebo for 6 months, followed by 6 months where everyone got inclisiran. The main goal was to see how much LDL cholesterol dropped after 150 days. The study is complete and aimed at managing cholesterol levels to reduce heart disease risk.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Novartis Investigative Site
Fuzhou, Fujian, 350025, China
-
Novartis Investigative Site
Guangzhou, Guangdong, 510000, China
-
Novartis Investigative Site
Guangzhou, Guangdong, 510515, China
-
Novartis Investigative Site
Zhongshan, Guangdong, 528403, China
-
Novartis Investigative Site
Wuhan, Hubei, 430022, China
-
Novartis Investigative Site
Changsha, Hunan, 410003, China
-
Novartis Investigative Site
Changsha, Hunan, 410011, China
-
Novartis Investigative Site
Hohhot, Inner Mongolia, 010017, China
-
Novartis Investigative Site
Changzhou, Jiangsu, 213004, China
-
Novartis Investigative Site
Xuzhou, Jiangsu, 221003, China
-
Novartis Investigative Site
Nanchang, Jiangxi, 330009, China
-
Novartis Investigative Site
Jinzhou, Liaoning, 121001, China
-
Novartis Investigative Site
Linyi, Shandong, 276000, China
-
Novartis Investigative Site
Taiyuan, Shanxi, 030002, China
-
Novartis Investigative Site
Xian, Shanxi, 710061, China
-
Novartis Investigative Site
Chengdu, Sichuan, 610041, China
-
Novartis Investigative Site
Tianjin, Tianjin Municipality, 300121, China
-
Novartis Investigative Site
Hangzhou, Zhejiang, 310006, China
-
Novartis Investigative Site
Beijing, 100029, China
-
Novartis Investigative Site
Beijing, 100034, China
-
Novartis Investigative Site
Beijing, 100730, China
-
Novartis Investigative Site
Beijing, 101200, China
-
Novartis Investigative Site
Jinan, 250012, China
-
Novartis Investigative Site
Shanghai, 200025, China
-
Novartis Investigative Site
Shanghai, 200080, China
-
Novartis Investigative Site
Shanghai, 200120, China
-
Novartis Investigative Site
Tianjin, 300052, China
-
Novartis Investigative Site
Tianjin, 300140, China
Conditions
Explore the condition pages connected to this study.